77 related articles for article (PubMed ID: 10101145)
21. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
23. Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats.
Fuksa L; Brcakova E; Cermanova J; Hroch M; Chladek J; Kolouchova G; Malakova J; Martinkova J; Staud F; Micuda S
Biopharm Drug Dispos; 2008 Jul; 29(5):289-99. PubMed ID: 18548509
[TBL] [Abstract][Full Text] [Related]
24. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
25. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.
Singh R; Chen IW; Jin L; Silva MV; Arison BH; Lin JH; Wong BK
Drug Metab Dispos; 2001 Dec; 29(12):1578-87. PubMed ID: 11717177
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
28. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
Komura H; Iwaki M
Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
[TBL] [Abstract][Full Text] [Related]
29. Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.
Ohta Y; Fukuda S; Makino H
Immunopharmacology; 1997 Oct; 37(2-3):167-74. PubMed ID: 9403335
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of flunixin in the cat: enterohepatic circulation and active transport mechanism in the liver.
Horii Y; Ikenaga M; Shimoda M; Kokue E
J Vet Pharmacol Ther; 2004 Apr; 27(2):65-9. PubMed ID: 15096102
[TBL] [Abstract][Full Text] [Related]
31. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of TDP223206 following intravenous and oral administration to intact rats and intravenous administration to bile duct-cannulated rats.
Chen Y; Cheng D; Marugan JJ; Manthey C; Tomczuk B; Huebert N
Biopharm Drug Dispos; 2008 May; 29(4):219-30. PubMed ID: 18260095
[TBL] [Abstract][Full Text] [Related]
33. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding.
Hiraoka H; Yamamoto K; Okano N; Morita T; Goto F; Horiuchi R
Clin Pharmacol Ther; 2004 Apr; 75(4):324-30. PubMed ID: 15060510
[TBL] [Abstract][Full Text] [Related]
34. Double column-switching high-performance liquid chromatographic method for the determination of TAK-603 and its metabolites in human serum.
Hagimoto T; Okada J; Motohashi M; Yoshimura Y
J Chromatogr B Biomed Sci Appl; 1998 Aug; 712(1-2):161-7. PubMed ID: 9698238
[TBL] [Abstract][Full Text] [Related]
35. Nonlinear pharmacokinetics of TAK-044, a new endothelin antagonist, in rats.
Takeuchi T; Tagawa Y; Hagihara K; Maeshiba Y; Yamashita K; Tsukuda R; Yoshimura Y
Biopharm Drug Dispos; 2001 Sep; 22(6):221-30. PubMed ID: 11754038
[TBL] [Abstract][Full Text] [Related]
36. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
[TBL] [Abstract][Full Text] [Related]
37. Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.
Cárcel-Trullols J; Torres-Molina F; Araico A; Saadeddin A; Peris JE
Cancer Chemother Pharmacol; 2004 Aug; 54(2):153-60. PubMed ID: 15114410
[TBL] [Abstract][Full Text] [Related]
38. TAK-603, an anti-inflammatory compound, reduces crescentic glomerulonephritis and preserves renal function in WKY rats.
Yamahana J; Wada T; Furuichi K; Sakai N; Yokoyama H; Kaneko S
Nephrol Dial Transplant; 2006 Oct; 21(10):2736-44. PubMed ID: 16891648
[TBL] [Abstract][Full Text] [Related]
39. The effects of the concentration-dependent erythrocyte distribution of TAK-802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics.
Kakehi M; Tagawa Y; Goto A; Kondo T; Asahi S
Biopharm Drug Dispos; 2016 Nov; 37(8):467-478. PubMed ID: 27554287
[TBL] [Abstract][Full Text] [Related]
40. Chemical reactivity of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242) in vitro.
Jinno F; Yoneyama T; Morohashi A; Kondo T; Asahi S
Biopharm Drug Dispos; 2011 Oct; 32(7):408-25. PubMed ID: 21887787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
